Commentary - (2025) Volume 16, Issue 6
Received: 03-Nov-2025, Manuscript No. jnmrt-26-186396;
Editor assigned: 05-Nov-2025, Pre QC No. P-186396;
Reviewed: 19-Nov-2025, QC No. Q-186396;
Revised: 24-Nov-2025, Manuscript No. R-186396;
Published:
01-Dec-2025
, DOI: 10.37421/2155-9619.2025.16.677
Citation: Hassan, Amira. ”PET Imaging in Pediatric Oncology:
Advancing Radionuclide Therapies.” J Nucl Med Radiat Ther 16 (2025):677.
Copyright: © 2025 Hassan A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution and reproduction in any medium, provided the original author and source are credited.
Positron Emission Tomography (PET) imaging has emerged as a powerful tool for visualizing and quantifying the uptake of therapeutic radionuclides in preclinical models of pediatric cancers, offering critical insights into biodistribution and target engagement. This advanced imaging modality is instrumental in optimizing radionuclide therapy for children, paving the way for more effective and personalized treatment strategies by accurately localizing radiotherapeutics and assessing their impact [1].
The integration of PET imaging with radiopharmaceutical therapy (RPT) is becoming increasingly crucial for the advancement of theranostics in pediatric oncology. PET's capability to non-invasively monitor the in vivo behavior of therapeutic radionuclides enables dose escalation and personalized treatment planning. This allows for the visualization of target-to-non-target ratios and early assessment of treatment response, representing a significant advancement in care [2].
In pediatric solid tumors, 18F-FDG PET/CT plays a vital role in evaluating the metabolic response to radionuclide therapy. Changes in glucose metabolism, as visualized by FDG uptake, serve as an early indicator of therapeutic efficacy, often preceding structural changes. This approach is critical for adapting treatment strategies in real time [3].
The selection of appropriate PET tracers for monitoring therapeutic radionuclide uptake in pediatric cancer models is of paramount importance. Research into novel PET probes that specifically bind to targets overexpressed in these cancers allows for precise visualization of therapeutic agent distribution and dose delivery, thereby minimizing systemic exposure and enhancing treatment precision [4].
Accurate quantification of biodistribution and dosimetry of therapeutic radionuclides in preclinical pediatric models using PET is essential for ensuring both safety and efficacy. This involves meticulous attention to methodologies and challenges in quantitative PET imaging, including image reconstruction, scatter correction, and partial volume correction, to obtain reliable data for treatment planning [5].
Targeted alpha therapy (TAT) for pediatric cancers, such as rhabdomyosarcoma, is being effectively evaluated using PET imaging to track the distribution of alpha-emitting radionuclides. PET can visualize the localized delivery of alpha emitters to tumor sites, providing a foundation for optimizing TAT protocols in aggressive pediatric malignancies [6].
The role of PET imaging in assessing the pharmacokinetics and biodistribution of radiolabeled antibodies used in pediatric oncology is also being explored. This work provides critical data on how these antibody-based therapies accumulate in tumor tissues versus healthy organs, enabling better prediction of treatment outcomes and management of potential toxicities [7].
PET imaging is instrumental in guiding radionuclide therapy selection and optimization for pediatric bone sarcomas. By visualizing the uptake of specific therapeutic radionuclides in tumor models, researchers can identify the most effective agents and treatment regimens tailored to individual tumor characteristics, promoting personalized radionuclide therapy [8].
The challenge of effectively delivering therapeutic radionuclides to pediatric brain tumors is being addressed through PET imaging. This modality is employed to track the penetration and retention of radiolabeled drugs within the brain tumor microenvironment, aiming to improve drug delivery strategies and assess therapeutic efficacy in preclinical models [9].
Preclinical development and validation of novel radiopharmaceuticals for PET imaging of therapeutic radionuclide uptake in pediatric Acute Lymphoblastic Leukemia (ALL) models are crucial. This research showcases how PET can monitor the distribution of these agents, aiding in the design of more effective radionuclide therapies for this common childhood malignancy [10].
The application of Positron Emission Tomography (PET) for visualizing the uptake of therapeutic radionuclides in preclinical pediatric cancer models is a key area of research. PET offers the ability to accurately quantify and localize these radiotherapeutics, providing crucial insights into their biodistribution, target engagement, and potential off-target effects, which is vital for optimizing radionuclide therapy in children and developing personalized treatment strategies [1].
The convergence of PET imaging with radiopharmaceutical therapy (RPT) is fundamental to advancing theranostics in pediatric oncology. This synergy allows for non-invasive monitoring of the in vivo behavior of therapeutic radionuclides, facilitating dose escalation and personalized treatment planning by visualizing target-to-non-target ratios and assessing treatment response early [2].
For pediatric solid tumors, the use of 18F-FDG PET/CT is critical for evaluating the metabolic response to radionuclide therapy. This imaging technique enables the detection of changes in glucose metabolism, serving as an early indicator of therapeutic efficacy even before structural changes are apparent, thereby allowing for timely adjustments to treatment [3].
The development and application of novel PET tracers are essential for monitoring therapeutic radionuclide uptake in pediatric cancer models. These specialized tracers are designed to specifically bind to targets overexpressed in pediatric cancers, enabling precise visualization of therapeutic agent distribution and targeted delivery to tumor cells, thus minimizing systemic exposure [4].
Quantitative PET imaging for radionuclide therapy dosimetry in preclinical pediatric models requires rigorous methodologies. Accurate quantification of biodistribution and dosimetry involves addressing challenges in image reconstruction, scatter correction, and partial volume correction to ensure reliable data essential for effective treatment planning and safety [5].
Targeted alpha therapy (TAT) is being investigated for pediatric cancers, and PET imaging plays a significant role in tracking the distribution of alpha-emitting radionuclides. This allows for the visualization of localized delivery to tumor sites, providing a basis for optimizing TAT protocols in aggressive pediatric cancers like rhabdomyosarcoma [6].
PET imaging is also being utilized to assess the pharmacokinetics and biodistribution of radiolabeled antibodies in pediatric oncology. This research provides critical data on how these therapies accumulate in tumor tissues versus healthy organs, aiding in the prediction of treatment outcomes and the management of potential toxicities [7].
In pediatric bone sarcomas, PET imaging is employed to guide the selection and optimization of radionuclide therapy. By visualizing the uptake of specific therapeutic radionuclides in tumor models, researchers can identify the most effective agents and treatment regimens tailored to individual tumor characteristics, promoting personalized approaches [8].
Addressing the challenge of delivering therapeutic radionuclides to pediatric brain tumors is another significant application of PET imaging. The modality is used to track the penetration and retention of radiolabeled drugs within the brain tumor microenvironment, aiming to improve drug delivery strategies and assess therapeutic efficacy [9].
Finally, the preclinical development and validation of novel radiopharmaceuticals for PET imaging in pediatric Acute Lymphoblastic Leukemia (ALL) models are underway. This research demonstrates how PET can effectively monitor the distribution of these agents, contributing to the design of more effective radionuclide therapies for this common childhood malignancy [10].
Positron Emission Tomography (PET) imaging is a vital tool in pediatric oncology, enabling precise visualization and quantification of therapeutic radionuclide uptake in preclinical models. This technology aids in understanding biodistribution, target engagement, and potential off-target effects, crucial for optimizing radionuclide therapy and personalizing treatment strategies. PET also facilitates theranostics by non-invasively monitoring radionuclide behavior, allowing for dose adjustments and early response assessment. Specific tracers and techniques like 18F-FDG PET/CT help evaluate metabolic response and guide therapy selection. PET imaging is instrumental in assessing targeted therapies, including alpha therapy and radiolabeled antibodies, and in tracking drug delivery to challenging sites like brain tumors. Overall, PET imaging is advancing the development of more effective and tailored radionuclide therapies for various pediatric cancers.
Nuclear Medicine & Radiation Therapy received 706 citations as per Google Scholar report
